Skip to main content
ELAB
NASDAQ Life Sciences

Director Graydon Bensler Discloses 7.4% Stake in PMGC Holdings via Options for Consulting Services

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.81
Mkt Cap
$8.224M
52W Low
$1.62
52W High
$309.12
52W Position info
12% above low
Off High info
99% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ELAB is trading near its 52-week low of $1.62 (12% above the low) on light trading volume (0.1× avg).

Summary

Director Graydon Bensler and his entity, GB Capital Ltd., have reported a new 7.40% stake in PMGC Holdings, primarily through options received as compensation for consulting services.


Key Events · Ownership and Investor Activity · ELAB

  • New Significant Insider Stake

    Director Graydon Bensler and GB Capital Ltd. disclosed a 7.40% beneficial ownership stake in PMGC Holdings Inc., totaling 450,287 shares.

  • Stake Acquired as Compensation

    The majority of this stake (450,277 shares) was acquired through options granted on June 1, 2026, as partial consideration for consulting services provided by GB Capital Ltd.

  • Substantial Value for Micro-Cap

    The reported stake is valued at approximately $815,000, representing nearly 10% of the company's current market capitalization.

  • Context of Financial Distress

    This disclosure follows recent filings indicating a "going concern" warning and multiple dilutive equity financing events for PMGC Holdings.


Analysis · ELAB · Life Sciences

Director Graydon Bensler, through his wholly-owned entity GB Capital Ltd., has disclosed a new 7.40% beneficial ownership stake in PMGC Holdings Inc. This stake, valued at approximately $815,000, was primarily acquired through options granted as partial compensation for consulting services. This significant insider ownership aligns Mr. Bensler's interests with the company's performance, particularly as the company navigates a "going concern" warning and recent dilutive financing activities.

At the time of this filing, ELAB was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $1.62 to $309.12. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELAB - Latest Insights

ELAB
Jul 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $0.9034 info
Change: -$0.1266 (-12%) info
Market Cap: $4.089M info
ELAB
Jul 07, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $0.9034 info
Change: -$0.2966 (-25%) info
Market Cap: $4.089M info
ELAB
Jul 06, 2026, 7:32 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.33
Real-time Price: $0.9034 info
Change: -$0.4253 (-32%) info
Market Cap: $4.089M info
ELAB
Jul 01, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.57
Real-time Price: $0.9034 info
Change: -$0.6666 (-42%) info
Market Cap: $4.089M info
ELAB
Jul 01, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.28
Real-time Price: $0.9034 info
Change: -$0.3766 (-29%) info
Market Cap: $4.089M info